TABLE 3.

Estimated specificity along with 95% confidence interval at controlled sensitivity level ${(\rho }_0)$ in the aggressive prostate cancer application

${\mathit{\rho }}_0$	${\widehat{\mathit{\varphi }}}_{\mathit{n}}$	$\stackrel{\mathit{ˆ}}{\mathit{\varphi }}$	${\stackrel{\mathit{ˆ}}{\mathit{\varphi }}}_{\mathit{r}\mathit{e}\mathit{g}}$	${\widehat{\mathit{\varphi }}}_{\mathit{R}\mathit{O}\mathit{C}}$
0.95	0.239	0.196 (0.108, 0.330)	0.208 (0.118, 0.340)	0.218 (0.127, 0.348)
0.90	0.284	0.318 (0.225, 0.429)	0.316 (0.223, 0.427)	0.321 (0.228, 0.431)
0.85	0.332	0.361 (0.297, 0.430)	0.358 (0.294, 0.428)	0.361 (0.297, 0.430)
0.80	0.392	0.398 (0.320, 0.481)	0.398 (0.320, 0.480)	0.400 (0.323, 0.483)

${\hat{\varphi }}_n$, estimated specificity without covariate adjustment; $\hat{\varphi }$, estimated specificity adjusting for age and AA without applying monotonicity restoration; ${\hat{\varphi }}_{reg}$ and ${\hat{\varphi }}_{\text{ROC}}$, covariate-adjusted specificity after applying regression- and ROC-based monotonization methods, respectively. The confidence interval is logit transformation-based with sample-based standard error